By Tarun Sai Lomte Reviewed by Lily Ramsey, LLM Jan 30 2025 A phase II trial found that T-VEC improved tumor resectability in 50% of patients, leading to early study discontinuation, with strong immune response activation and minimal side effects. Study:  Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial) . Image Credit: Kateryna Kon/Shutterstock.com In a recent study published in Nature Cancer ,